/
Ophthalmology
Diabetic Retinopathy
30
Pipeline Programs↗
34
Active Trials↗
24
Companies Involved↗
Diabetic Retinopathy is an emerging landscape with 30 programs across 24 companies. The most active players are Santen Pharmaceutical Co., Ltd., Haisco Pharmaceutical Group Co., Ltd., Hudson Biotech. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 15
Phase 23
Phase 34
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
21 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 87% of 30 pipeline programs.
Analysis
Trial Status
180
clinical trials
Completed96 · 53%
Unknown status32 · 18%
Recruiting14 · 8%
Terminated14 · 8%
Active, not recruiting9 · 5%
Not yet recruiting8 · 4%
Other7 · 4%
Clinical Trials
Trial Activity
180 trials
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
Recruiting·—·Phase 1·NCT06412224·6 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)